← Back to Clinical Trials
Recruiting NCT06141135

NCT06141135 GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06141135
Status Recruiting
Phase
Sponsor Genomic Prediction Inc.
Condition Infertility, Female
Study Type INTERVENTIONAL
Enrollment 240 participants
Start Date 2023-11-15
Primary Completion 2025-11-15

Eligibility & Interventions

Sex Female only
Min Age 35 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
Preimplantation genetic testing for aneuploidy (PGTA)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 240 participants in total. It began in 2023-11-15 with a primary completion date of 2025-11-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer in women between 35 and 40 years of age.

Eligibility Criteria

Inclusion Criteria: * Women undergoing IVF of between 35 and 40 years of age at IVF cycle start * Utilization of Intracytoplasmic Sperm Injection ICSI (recommended) or ---Traditional IVF * Utilization of ejaculated or testicular sperm * Utilization of autologous or donor sperm * All Controlled Ovarian Hyperstimulation (COH) protocols Exclusion Criteria: * Utilization of donor oocytes * Utilization of gestational carrier * Recurrent Pregnancy Loss (RPL) defined as ≥ 3 consecutive miscarriages * Recurrent Implantation Failure (RIF) defined as ≥ 3 more failed embryo transfers * Preimplantation genetic testing for monogenic/single gene disorders (PGT-M) * Translocation carriers

Contact & Investigator

Central Contact

Talia Metzgar

✉ talia@genomicprediction.com

📞 (973) 529- 4223

Principal Investigator

Nathan Treff, PhD

PRINCIPAL INVESTIGATOR

Genomic Prediction Clinical Labortory

Frequently Asked Questions

Who can join the NCT06141135 clinical trial?

This trial is open to female participants only, aged 35 Years or older, up to 40 Years, studying Infertility, Female. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06141135 currently recruiting?

Yes, NCT06141135 is actively recruiting participants. Contact the research team at talia@genomicprediction.com for enrollment information.

Where is the NCT06141135 trial being conducted?

This trial is being conducted at Waltham, United States.

Who is sponsoring the NCT06141135 clinical trial?

NCT06141135 is sponsored by Genomic Prediction Inc.. The principal investigator is Nathan Treff, PhD at Genomic Prediction Clinical Labortory. The trial plans to enroll 240 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology